Other VEGF/VEGFR inhibitors that have been tested in high-grade glioma preclinical models are cabozantinib, which reduces proliferation and migration and induces apoptosis in DIPG cell lines [90]; foretinib, which inhibits tumor growth in animal models of glioblastoma [91]; and aflibercept, which increases Ang2 expression in glioblastoma murine models, but in combination with trebananib increases survival, reduces permeability and the amount of tumor-associated macrophages, improves mural cell coverage, and increases lymphocyte infiltration [92]. This evidence concerns the gene KDR and glioblastoma.